NCT02569372View on ClinicalTrials.gov

A Phase 1 Study of GC1102 (Recombinant Hepatitis B Immunoglobulin) in Chronic Hepatitis B Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

November 9, 2015

Primary Completion Date

October 12, 2017

Study Completion Date

October 12, 2017

Conditions
Chronic Hepatitis B
Interventions
BIOLOGICAL

GC1102

GC1102(Recombinant Hepatitis B Human Immunoglobulin)

Trial Locations (1)

Unknown

Severance Hospital, Seoul

Sponsors
All Listed Sponsors
lead

Green Cross Corporation

INDUSTRY

NCT02569372 - A Phase 1 Study of GC1102 (Recombinant Hepatitis B Immunoglobulin) in Chronic Hepatitis B Patients | Biotech Hunter | Biotech Hunter